Publications and Presentations

This list details many of the research publications and presentations by Institute members during the past financial year. The list is intended to illustrate the extensive range of research conducted by our dermatologists, registrars and research fellows.

2022/2023

Chong, A. H. Mumford, B. P., Unglik, G. A. & Khamu, T. T.
(2023). A preauricular erythematous indurated plaque. Clinical and Experimental Dermatology, 48(6), 717–719. https://doi.org/10.1093/ced/llad064

Chong, A. H., Allen, N. C., Martin, A. J., Snaidr, V. A., Eggins,R., Fernandéz-Peñas, P., Gin, D., Sidhu, S., Paddon, V. L., Banney, L. A., Lim, A., Upjohn, E., Schaider, H.,
Ganhewa, A. D., Nguyen, J., McKenzie, C. A., Prakash, S., McLean, C., Lochhead, A., … Damian, D. L. (2023). Nicotinamide for skin-cancer chemoprevention
in transplant recipients. New England Journal of Medicine, 388(9), 804–812. https://doi.org/10.1056/nejmoa2203086

Adamson, S. R., Davenport, R., Foley, P., & Chong, A. (2022, July). Scalp pruritus – scratching for answers.  Medicine Today.  https://medicinetoday.com.au/mt/2022/july/feature-article/scalp-pruritus-%E2%80%93-scratching-answers

Willems , A., & Chong, A. (2023, April 23). Podcast innovation in medical education. Pursuit. https://pursuit.unimelb.
edu.au/articles/podcast-innovation-in-medicaleducation


Adamson, S. R., Foley, P., & Chong, A. (2022, October). Actinic keratoses – a guide to treatment with 5-Fluorouracil Cream.  | Medicine Today. https://medicinetoday.com.au/mt/2022/october/regular-series/actinic-keratoses-%E2%80%93-guide-treatment-5fluorouracil-cream

Foley, P., Gebauer, K., Sullivan, J., McMeniman, E., Shumack, S., Ng, J., James, A., Rawlin, M., Sidhu, S., Tilakaratne, D., Turner, M., Radulski, B., Nash, P., & Baker, C. (2023). Australian consensus: Treatment goals for moderate to severe psoriasis in the era of targeted therapies – adult patients. Australasian Journal of Dermatology. https://doi.org/10.1111/ajd.14138

Spelman, L., Potter, A. E., Baker, C., Shumack, S., Sinclair, R., Christie, D., Wong, B., Foley, P., Hacker, S., & Allison, C. C. (2023). Efficacy and safety analysis: 24‐month outcomes from a prospective cohort of 106 fields treated with widefield radiation therapy for extensive skin field cancerization, with or without keratinocyte cancers. JEADV Clinical Practice. https://doi.org/10.1002/jvc2.312

Foley, P., Felmingham, C., Pan, Y., Kok, Y., Kelly, J., Gin, D., Nguyen, J., Goh, M., Chamberlain, A., Oakley, A., Tucker, S., Berry, W., Darling, M., Jobson, D., Robinson, A., de Menezes, S., Wang, C., Willems, A., McLean, C., Cranwell, W., … Zallmann, M. (2023). Improving skin cancer management with artificial intelligence: A pre[1]post intervention trial of an artificial intelligence system used as a diagnostic aid for skin cancer management in a real-world specialist dermatology setting. Journal of the American Academy of Dermatology, 88(5), 1138– 1142. https://doi.org/10.1016/j.jaad.2022.10.038

 

 Foley, P., Strober, B., Tada, Y., Mrowietz, U., Lebwohl, M., Langley, R. G., Warren, R. B., Wang, M., Vanvoorden, V., Szilagyi, B., Ciaravino, V., & Paul, C. (2023). BIMEKIZUMAB maintenance of response through 3 years in patients with moderate-to-severe plaque psoriasis: Results from the be bright open-label extension trial. British Journal of Dermatology, 188(6), 749–759. https://doi.org/10.1093/bjd/ljad035

Adamson, S. R., Davenport, R., Foley, P., & Chong, A. (2022, July). Scalp pruritus – scratching for answers. Scalp pruritus – scratching for answers | Medicine Today. https:// medicinetoday.com.au/mt/2022/july/feature-article/ scalp-pruritus-%E2%80%93-scratching-answers

Reich, K., Gordon, K. B., Strober, B., Langley, R. G., Miller, M., Yang, Y. -W., Shen, Y. -K., You, Y., Zhu, Y., Foley, P., & Blauvelt, A. (2022). Super-response to guselkumab treatment in patients with moderate-to-severe psoriasis: Age, body weight, baseline psoriasis area and severity index, and Baseline Investigator’s global assessment scores predict complete skin clearance. Journal of the European Academy of Dermatology and Venereology, 36(12), 2393– 2400. https://doi.org/10.1111/jdv.18474

Foley, P., Manuelpillai, N., Dolianitis, C., Cains, G. D., Mate, E., Tronnberg, R., & Baker, C. (2022). Secukinumab treatment demonstrated high drug survival and sustained effectiveness in patients with severe chronic plaque psoriasis: 21-month analysis in Australian routine clinical practice (sustain study). Australasian Journal of Dermatology, 63(3), 303–311. https://doi.org/10.1111/ ajd.13895

Adamson, S. R., Foley, P., & Chong, A. (2022, October). Actinic keratoses – a guide to treatment with 5-Fluorouracil Cream. Actinic keratoses – a guide to treatment with 5-fluorouracil cream | Medicine Today. https:// medicinetoday.com.au/mt/2022/october/regular-series/ actinic-keratoses-%E2%80%93-guide-treatment[1]5fluorouracil-cream

Strober, B., Thaçi, D., Sofen, H., Kircik, L., Gordon, K. B., Foley, P., Rich, P., Paul, C., Bagel, J., Colston, E., Throup, J., Kundu, S., Sekaran, C., Linaberry, M., Banerjee, S., & Papp, K. A. (2023). Deucravacitinib versus Placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double[1]blinded, phase 3 program for evaluation of TYK2 inhibitor psoriasis second trial. Journal of the American Academy of Dermatology, 88(1), 40–51. https://doi.org/10.1016/j. jaad.2022.08.061

Mahar, P. D., Egeberg, A., Merola, J. F., Schäkel, K., Puig, L., Wang, I. Y., Pavo, I., Schuster, C., & Griffiths, C. E. (2023). Efficacy of ixekizumab in patients with moderate-to-severe plaque psoriasis and prediabetes or type 2 diabetes. Frontiers in Medicine, 9. https://doi.org/10.3389/fmed.2022.1092688

Mahar, P., Vasanthan, R., Grigoris, I., & Myint, E. (2023). Erythema nodosum associated with terbinafine therapy- A case report. Journal of Dermatology Research, 1–5. https://doi.org/10.46889/jdr.2023.4104

Mahar, P. D., Panaccio, D. C., Dean, J. M., Farmer, C. C., Pang, S. C., & Kevat, D. A. (2022). Managing negative online reviews: Considerations for doctors. Australian Journal of General Practice, 51(8), 568–570. https:// doi.org/10.31128/ajgp-10-21-6215

Ting S, Nguyen J, Palmer A, Nixon R. Contact sensitisation in oral lichen planus: An Australian perspective. Contact Dermatitis Jun 13. doi: 10.1111/cod.14366.

Kaur A, Nixon R, Palmer A. Occupational allergic contact dermatitis: Are there emerging allergens?. Current Allergy & Clinical Immunology. 2023;36(2).

Kaur, A, Nixon, R. Dermographism from N95 surgical masks contributing to facial rashes in healthcare workers. Contact Dermatitis. 2023; 89:124- 127.

Kaur, A, Nixon, R. Allergic contact dermatitis to mercaptobenzothiazole in N95 mask rubber straps in healthcare workers. Contact Dermatitis 2023; 89: 70- 74.

Patel K, Nixon R. Irritant Dermatitis. Current Allergy and Clinical Immunology Journal 2023; 36(2). Lejding T, Persson L, Anderson KE et al Analysis of hexavalent chromium in cement Samples from countries within and outside the EU: A study from the International Contact Dermatitis Research Group. Dermatitis 2023; Mar 31 doi: 10.1089/derm.2022.0053.

Patel K, Palmer A, Nixon R. Allergic contact dermatitis from propylene glycol: a case series from Australia. Contact Dermatitis. doi: 10.1111/cod.14325. Epub 2023 Apr 26.

Dear K, Felmingham C, Ronaldson C, Nixon R. Presentations to emergency departments in Melbourne, Australia diagnosed as allergic contact dermatitis. Contact Dermatitis 2022; 88: 145-149.

Patel K, Nixon R. Scratch patch testing to Dermabond in a patient with suspected allergic contact dermatitis. Dermatitis 2023; 34: 250-251.

Patel K, Nixon R. Allergic contact dermatitis to an epidural catheter but what’s the allergen? A case report. Contact Dermatitis 2022; 87: 462-464.

Dear K, D. Gan, A. Stavrakoglou, R. Nixon, C. Ronaldson. Hyperkeratotic flexural erythema (more commonly known as granular parakeratosis) with use of laundry rinses containing benzalkonium chloride – a case series. Clin Exp Derm 2022; 47: 2196-2200

 

Kern, J. S., Tam, M., & Jiang, J. (2023). A simple solution for habit-tic nail deformity. Australasian Journal of Dermatology, 64(3). https://doi.org/10.1111/ajd.14077

Kern, J. S., Tan, C., Prakash, S., Howard, A., & Arasu, A. (2023). Clinical and dermoscopic features of nail unit melanoma in an australian nail clinic cohort. Australasian Journal of Dermatology, 64(3), 417–422. https://doi.org/10.1111/ajd.14057

Kern, J. S., Low, Z. M., Koye, D. N., Haurat, J., Ioppi, B., Antunes, E., Fazio, T. N., Nicolopoulos, J., Dolianitis, C., Howard, A., Radulski, B., Scardamaglia, L., & Morgan, V. (2023). Evaluation of teledermatology during a pandemic: Assessing patient satisfaction, cost evaluation and Clinical Effectiveness. Australasian Journal of Dermatology, 64(2). https://doi.org/10.1111/ajd.14004

Kern, J. S., Gamell, C., Bankovacki, A., Scalzo-Inguanti, K., Sedgmen, B., Alhamdoosh, M., Gail, E., Turkovic, L., Millar, C., Johnson, L., Wahlsten, M., Richter, J., Schuster, J., Dyson, A., Nicolopoulos, J., Varigos, G., Ng, M., Wilson, N., Field, J., & Lindqvist, L. M. (2023). CSL324, a granulocyte colony-stimulating factor receptor antagonist, blocks neutrophil migration markers that are upregulated in Hidradenitis Suppurativa. British Journal of Dermatology, 188(5), 636–648. https://doi.org/10.1093/bjd/ljad013

Kern, J., James, F., Goh, M. S., Mouhtouris, E., Vogrin, S., Chua, K. Y., Holmes, N. E., Awad, A., Copaescu, A.-M., De Luca, J. F., Zubrinich, C., Gin, D., Cleland, H., Douglas, A., S., Katelaris, C. H., Thien, F., Barnes, S., Yun, J., Tong, W., … Trubiano, J. (2022). Study protocol: Australasian registry of severe cutaneous adverse reactions (aus-scar). BMJ Open, 12(8). https://doi.org/10.1136/ bmjopen-2021-055906

Kern, J. S., Yun, J. S., Howard, A., & Prakash, S. (2022). Clinical and histopathological features of onychopapilloma in an Australian setting: A case series of 50 patients. Australasian Journal of Dermatology, 63(4). https://doi. org/10.1111/ajd.13900

Kern, J. S., McComish, J. S., Slade, C. A., Buizen, L., Paul, S. K., Chatelier, J. W., Unglik, G., Nicholls, K. A., Spriggs, K., Chan, S. S., Godsell, J., Auyeung, P., Tan, Z. H., DeLuca, J., Patel, M., Kuek, L. E., Tran, Y., Scardamaglia, L., Varigos, G. A., … Douglass, J. A. (2023). Randomized controlled trial of omalizumab in treatment-resistant systemic and cutaneous mastocytosis (roam). The Journal of Allergy and Clinical Immunology: In Practice, 11(7). https://doi.org/10.1016/j.jaip.2023.04.008

Allen, N. C., Martin, A. J., Snaidr, V. A., Eggins, R., Chong, A. H., Fernandéz-Peñas, P., Gin, D., Sidhu, S., Paddon, V. L., Banney, L. A., Lim, A., Upjohn, E., Schaider, H., Ganhewa, A. D., Nguyen, J., McKenzie, C. A., Prakash, S., McLean, C., Lochhead, A., … Damian, D. L. (2023). Nicotinamide for skin-cancer chemoprevention in transplant recipients. New England Journal of Medicine, 388(9), 804–812. https://doi.org/10.1056/nejmoa2203086

2021/2022

Chong, A. H. , Allnutt, K. J., Vogrin, S., Li, J., Goh, M. S., Brennand, S., Davenport, R. (2022). A long‐term cohort study of acitretin for prevention of keratinocyte carcinoma in solid organ transplant recipients. Australasian Journal of Dermatology, 63(2). https://doi.org/10.1111/ajd.13821

Chong, A. H., Mumford, B. P. (2022). A rash of poor cooking. Australian Journal of General Practice, 51(3), 143–144. https://doi.org/10.31128/ajgp-03-21-5901

Chong, A. H., Massey, P. R., Schmults, C. D., Li, S. J., Arron, S. T., Asgari, M. M., Bouwes Bavinck, J. N., Billingsley, E., Blalock, T. W., Blasdale, K., Carroll, B. T., Carucci, J. A., Christensen, S. R., Chung, C. L., DeSimone, J. A., Ducroux, E., Escutia-Muñoz, B., Ferrándiz-Pulido, C., Fox, M. C., … Jambusaria-Pahlajani, A. (2021). Consensus-based recommendations on the prevention of squamous cell carcinoma in solid organ transplant recipients. JAMA Dermatology, 157(10), 1219. https://doi.org/10.1001/jamadermatol.2021.3180

Chong, A., Mumford, B. P., Ryan, A., & Lasocki, A. (2022). Follicular mucinosis with novel dermoscopic finding: The toothpaste sign. Clinical and Experimental Dermatology, 47(5), 969–970. https://doi.org/10.1111/ced.15083

Sun, Q., McMahon, D. E., Ugwu-Dike, P. O., Sun, Q., Tang, K., Zhang, H., Suchonwanit, P., Oh, C. C., Chong, A. H., Willems, A., Galván, C., Dodiuk-Gad, R. P., Fantini, F., Recalcati, S., Avancini, J., Miyamoto, D., Sanches, J. A., Raboobee, N., Bravo, F., & Freeman, E. E. (2021). How coronavirus disease 2019 changed dermatology practice in 1 year around the world. Dermatologic Clinics, 39(4), 639–651. https://doi.org/10.1016/j.det.2021.05.014

Willems, A. and Chong, A., 2022, May. The rise and rise of FOAMeD in dermatology education-A review. In AUSTRALASIAN JOURNAL OF DERMATOLOGY (Vol. 63, pp. 58-58).

Willems, A. and Chong, A., 2022, May. Australian General Practitioners’ continuing professional development in dermatological conditions: A Review. In AUSTRALASIAN JOURNAL OF DERMATOLOGY (Vol. 63, pp. 104-104)

 Willems, A., Chong, AH., The rise of dermatology FOAMed in the pandemic landscape. Partyline. Issue 79, June 2022.

Willems, A., Chong, AH., Teledermatology: The way of the future? Partyline. Issue 78, March 2022.

Sun, Q., McMahon, D.E., Ugwu-Dike, P.O., Sun, Q., Tang, K., Zhang, H., Suchonwanit, P., Oh, C.C., Chong, A.H., Willems, A., Galván, C. et al., 2021. How COVID-19 Changed Dermatology Practice in One Year Around the World: Perspectives From 11 Countries. Dermatologic Clinics

 

Ryan, C., Guenther, L., Foley, P., Weisman, J., Burge, R. T., Gallo, G., See, K., McKean‐Matthews, M., Bertram, C. C., & Merola, J. F. (2021). Ixekizumab provides persistent improvements in health‐related quality of life and the sexual impact associated with moderate‐to‐severe genital psoriasis in adult patients during a 52‐week, randomised, placebo‐controlled, phase 3 clinical trial. Journal of the European Academy of Dermatology and Venereology, 36(4). https://doi.org/10.1111/jdv.17836

Reich, K., Gordon, K. B., Strober, B., Langley, R. G., Miller, M., Yang, Y. W., Shen, Y. K., You, Y., Zhu, Y., Foley, P., & Blauvelt, A. (2022). Super‐response to guselkumab treatment in patients with moderate‐to‐severe psoriasis: Age, body weight, baseline psoriasis area and severity index, and Baseline Investigator’s global assessment scores predict complete skin clearance. Journal of the European Academy of Dermatology and Venereology. https://doi.org/10.1111/jdv.18474

 

Foley, P., Chong, A. H., Davenport, R., & Adamson, S. R. (2022, July 1). Scalp pruritus – scratching for answers. Medicine Today. Retrieved September 21, 2022, from https://medicinetoday.com.au/2022/july/feature-article/scalp-pruritus-scratching-answers

Thaçi, D., Strober, B., Gordon, K. B., Foley, P., Gooderham, M., Morita, A., Papp, K. A., Puig, L., Menter, M. A., Colombo, M. J., Elbez, Y., Kisa, R. M., Ye, J., Napoli, A. A., Wei, L., Banerjee, S., Merola, J. F., & Gottlieb, A. B. (2022). Deucravacitinib in moderate to severe psoriasis: Clinical and quality-of-life outcomes in a phase 2 trial. Dermatology and Therapy, 12(2), 495–510. https://doi.org/10.1007/s13555-021-00649-y

Foley, P., Tsai, T.-F., Rodins, K., Hamadah, I. R., Ammoury, A., Dayem, H. A., Abdallah, M., Crowe, S., Haas, S., Pournara, E., Jagiello, P., & Huang, Y.-H. (2022). Effectiveness and safety of secukinumab for psoriasis in a real-world clinical setting in the Asia-Pacific and Middle East regions: Results from the Realia Study. Dermatology and Therapy, 12(2), 511–527. https://doi.org/10.1007/s13555-021-00675-w

Foley, P., Manuelpillai, N., Dolianitis, C., Cains, G. D., Mate, E., Tronnberg, R., & Baker, C. (2022). Secukinumab treatment demonstrated high drug survival and sustained effectiveness in patients with severe chronic plaque psoriasis: 21‐month analysis in Australian routine clinical practice ( sustain study). Australasian Journal of Dermatology, 63(3), 303–311. https://doi.org/10.1111/ajd.13895

 

Murrell, D. F., Patsatsi, A., Stavropoulos, P., Zeeli, T., Kern, J. S., Sinclair, R., Neale, A., Arora, P., Sugerman, P. B., Shi, G., Werth, V. P., Caux, F., Joly, P., & Baum, S. (2022). Phase 2 believe study part B: Efficacy and safety of rilzabrutinib for patients with pemphigus vulgaris. Journal of the European Academy of Dermatology and Venereology, 36(10). https://doi.org/10.1111/jdv.18318

Gretzmeier, C., Pin, D., Kern, J. S., Chen, M., Woodley, D. T., Bruckner-Tuderman, L., de Souza, M. P., & Nyström, A. (2022). Systemic collagen VII replacement therapy for advanced recessive dystrophic epidermolysis bullosa. Journal of Investigative Dermatology, 142(4). https://doi.org/10.1016/j.jid.2021.09.008

Simpson, K., Low, Z. M., Yap, T., Kern, J. S., & Scardamaglia, L. (2021). Ultralow‐dose rituximab in pemphigus: A single‐centre experience. British Journal of Dermatology, 186(3), 581–583. https://doi.org/10.1111/bjd.20819

Schauer, F., Mai, S., Hofmann, S. C., Mai, Y., Izumi, K., Kern, J. S., & Kiritsi, D. (2022). Autoreactivity to BP180 neoepitopes in patients with pemphigoid gestationis. JAMA Dermatology, 158(2), 212. https://doi.org/10.1001/jamadermatol.2021.5294

McClatchy, J., Yap, T., Koo, K., Kern, J. S., & Scardamaglia, L. (2021). De-escalation of anti-CD20 monoclonal antibody (rituximab) protocols in PEMPHIGUS VULGARIS – a systematic review. Expert Opinion on Biological Therapy, 21(12), 1591–1601. https://doi.org/10.1080/14712598.2021.1937118

Low, Z. M., Scardamaglia, L., Morgan, V., & Kern, J. S. (2021). Australian teledermatology experience during COVID‐19. Australasian Journal of Dermatology, 62(4). https://doi.org/10.1111/ajd.13681

Murrell, D. F., Patsatsi, A., Stavropoulos, P., Baum, S., Zeeli, T., Kern, J. S., Roussaki‐Schulze, A. V., Sinclair, R., Bassukas, I. D., Thomas, D., Neale, A., Arora, P., Caux, F., Werth, V. P., Gourlay, S. G., & Joly, P. (2021). Proof of concept for the clinical effects of oral rilzabrutinib, the first Bruton tyrosine kinase inhibitor for pemphigus vulgaris: The phase II believe study*. British Journal of Dermatology, 185(4), 745–755. https://doi.org/10.1111/bjd.20431

Simpson, K., Low, Z. M., Howard, A., & Kern, J. S. (2021). Successful management of treatment resistant nail psoriasis with tildrakizumab. Australasian Journal of Dermatology, 62(3), 390–393. https://doi.org/10.1111/ajd.13642

Simpson, K., Scardamaglia, L., Kok, Y., Vu, M., Kidd, D., Yap, T., Tran, Y., & Kern, J. S. (2021). Comparison of the EUROIMMUN dermatology profile Elisa to the novel Biochip Mosaic 7 for the diagnosis of immunobullous skin disease. Australasian Journal of Dermatology, 62(3), 314–322. https://doi.org/10.1111/ajd.13611

Williams, C., Hunt, J., Kern, J. S., & Dunn, R. (2021). A CASEMIX study of patients seen within an urban Aboriginal Health Service Dermatology Clinic over a five‐year period. Australasian Journal of Dermatology, 62(3), 331–335. https://doi.org/10.1111/ajd.13630

 

Dear, K., Gan, D., Stavrakoglou, A., Nixon, R., & Ronaldson, C. (2022). Hyperkeratotic flexural erythema (more commonly known as granular parakeratosis) with use of laundry rinses containing benzalkonium chloride – a case series. Clinical and Experimental Dermatology. https://doi.org/10.1111/ced.15358

Punchewa N, Palmer A, Nixon R. Allergic contact dermatitis to Compositae: an Australian case series. Contact Dermatitis 2022; DOI: 10.1111/cod.14162

Mizutani H, Felmingham C, Palmer A, Tate B, Tam MM, Nixon R. Allergic contact cheilitis in Melbourne, Australia. Contact Dermatitis 2022; DOI: 10.1111/cod.14165.

Patel, K., Nixon, R. Irritant contact dermatitis — a review. Curr Derm Rep 2022; 11, 41–51.

Patel K, Nixon R. Mask exemptions for facial skin diseases – are they warranted?  Med J Aust 2022; 216 (9): DOI: 10.5694/mja2.51513.

Patel K, Nixon R. Allergic contact dermatitis to black rubber in firefighters’ masks: A case series. Contact Dermatitis 2022; 86; 136-7.

Nguyen J, Nixon R, Lee A. Allergic contact dermatitis caused by polyurethane components in bulletproof glass manufacturing. Contact Dermatitis; 86(4):325-326.

Agner T et al. Guidelines for diagnosis, prevention and treatment of hand eczema
Contact Dermatitis; 86: 357-378.

Chiu FPC, Nixon R, Lee A, Boyce A. “High-vis” dermatitis. Contact Dermatitis DOI: 10.1111/cod.14033

Patel K, Shimmin A, Nixon RL. Testing to Dermabond pre-operatively to reduce the likelihood of allergic skin reactions. ANZ J Surg 2021;91(11):2548-2549.

Ng KL, Grills C, Tam MM, Nixon R. A solution using Stomadhesive® wafers for allergic contact dermatitis caused by isobornyl acrylate in glucose monitoring sensors. Australas J Dermatol 63(1):e56-e59.

Scheinman, P.L., Vocanson, M., Thyssen, J.P. Vocanson M, Thyssen JP, Johansen JD, Nixon RL, Dear K, Botto, Morort, Goldminx A. Contact Dermatitis. Nat Rev Dis Primers 7, 38 (2021).                 https://doi.org/10.1038/s41572-021-00271-4

Ng KL, Nixon RL, Grills C, Tam MM. Solution using Stomahesive® wafers for allergic contact dermatitis caused by isobornyl acrylate in glucose monitoring sensors. Australas J Dermatol 2022 Feb;63(1):e56-e59.

Nixon, R., & Patel, K. (2021, July). Irritant contact dermatitis. DermNet.  https://dermnetnz.org/topics/irritant-contact-dermatitis

Nixon, R., & Ronaldson, C. (2021, August). House dust mite. DermNet. Retrieved September 26, 2022, from https://dermnetnz.org/topics/house-dust-mite

Nixon, R., & Danielle, M. G. (2022). Australian Standards for Protective Gloves. In R. N. Phalen & H. I. Maibach (Eds.), Protective gloves for occupational use. CRC Press.

 

Mizutani H, Nguyen J, Tam MM, Tate B, Cahill J, Nixon R.  Patch test reactivity to iodopropynyl butylcarbamate between 2011 and 2018 in Melbourne, Australia. Contact Dermatitis 2021 Nov;85(5):604-606.

Mactaggart E, Orchard D, Tam MM. Baby wipes and nappy rash – what is the relationship? A review. Australas J Dermatol 2021 Nov;62(4):470-477

Ting S, Tam M, Kelly R. Scarring in pyoderma gangrenosum. Australas J Dermatol 2021 Nov;62(4):523-525

Mactaggart E, Orchard D, Tam MM. Baby wipes and nappy rash – what is the relationship? A review. Australas J Dermatol 2021 Nov;62(4):470-477

Ting S, Tam M, Kelly R. Scarring in pyoderma gangrenosum. Australas J Dermatol 2021 Nov;62(4):523-525

 

Mahar PD, Panaccio DCA, Dean JM, Farmer CC, Pang CP, Kevat DAS. Managing negative online reviews: considerations for doctors. Australian Journal of General Practice 2022;(58)2:568-570

 Mahar PD, Zubrinich C, Manuelpillai N, Foley P. Combination treatment with monoclonal antibodies: Secukinumab, benralizumab and dupilumab for the combined management of psoriasis and severe asthma. Australasian Journal of Dermatology 2021; 62(4): 506-508

Kevat DAS, Farmer CC, Mahar PD, Panaccio DCA. Legal and ethical pitfalls in mandatory vaccination of residential aged care facility workers. MJA Insight+ 2021; 25

 Kevat DAS, Panaccio DCA, Pang SC, Dean JM, Farmer CF, Mahar PD. Medicolegal considerations of mandatory COVID-19 vaccination for high-risk workers. Medical Journal of Australia 2021; 215(1):45(5):622-626

 

Punchihewa N, Odhavji S, Upjohn E, Bekhor P. Immunostained Frozen Sections Vs Traditional Permanent Paraffin Sections for Lentigo Maligna Treated With Mohs Micrographic Surgery. Dermatol Surg. 2022 Jan 1;48(1):43-46. doi: 10.1097/DSS.0000000000003280. PMID: 34772830.

 

Scroll to Top